biosimilars newco limited
biosimilars newco limited Company Information
Company Number
14259834
Next Accounts
Dec 2025
Industry
Wholesale of pharmaceutical goods
Manufacture of other organic basic chemicals
Shareholders
biocon biologics limited
biocon biologics uk limited
Group Structure
View All
Contact
Registered Address
16 great queen street, covent garden, london, WC2B 5AH
Website
-biosimilars newco limited Estimated Valuation
Pomanda estimates the enterprise value of BIOSIMILARS NEWCO LIMITED at £987.9m based on a Turnover of £398.1m and 2.48x industry multiple (adjusted for size and gross margin).
biosimilars newco limited Estimated Valuation
Pomanda estimates the enterprise value of BIOSIMILARS NEWCO LIMITED at £0 based on an EBITDA of £-57.4m and a 12.36x industry multiple (adjusted for size and gross margin).
biosimilars newco limited Estimated Valuation
Pomanda estimates the enterprise value of BIOSIMILARS NEWCO LIMITED at £2b based on Net Assets of £1b and 1.93x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Biosimilars Newco Limited Overview
Biosimilars Newco Limited is a live company located in london, WC2B 5AH with a Companies House number of 14259834. It operates in the manufacture of other organic basic chemicals sector, SIC Code 20140. Founded in July 2022, it's largest shareholder is biocon biologics limited with a 68.4% stake. Biosimilars Newco Limited is a startup, mega sized company, Pomanda has estimated its turnover at £398.1m with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Biosimilars Newco Limited Health Check
Pomanda's financial health check has awarded Biosimilars Newco Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs
6 Strong
1 Regular
4 Weak
Size
annual sales of £398.1m, make it larger than the average company (£26.4m)
£398.1m - Biosimilars Newco Limited
£26.4m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Biosimilars Newco Limited
- - Industry AVG
Production
with a gross margin of 48.5%, this company has a lower cost of product (32.9%)
48.5% - Biosimilars Newco Limited
32.9% - Industry AVG
Profitability
an operating margin of -14.4% make it less profitable than the average company (1.7%)
-14.4% - Biosimilars Newco Limited
1.7% - Industry AVG
Employees
with 1337 employees, this is above the industry average (61)
- Biosimilars Newco Limited
61 - Industry AVG
Pay Structure
on an average salary of £425.2, the company has a lower pay structure (£71.5k)
- Biosimilars Newco Limited
£71.5k - Industry AVG
Efficiency
resulting in sales per employee of £297.7k, this is less efficient (£449k)
- Biosimilars Newco Limited
£449k - Industry AVG
Debtor Days
it gets paid by customers after 206 days, this is later than average (52 days)
206 days - Biosimilars Newco Limited
52 days - Industry AVG
Creditor Days
its suppliers are paid after 46 days, this is slower than average (35 days)
46 days - Biosimilars Newco Limited
35 days - Industry AVG
Stock Days
it holds stock equivalent to 4 days, this is less than average (71 days)
4 days - Biosimilars Newco Limited
71 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (14 weeks)
0 weeks - Biosimilars Newco Limited
14 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 49.5%, this is a similar level of debt than the average (48.2%)
49.5% - Biosimilars Newco Limited
48.2% - Industry AVG
BIOSIMILARS NEWCO LIMITED financials
Biosimilars Newco Limited's latest turnover from March 2024 is £398.1 million and the company has net assets of £1 billion. According to their latest financial statements, we estimate that Biosimilars Newco Limited has 1,337 employees and maintains cash reserves of £2.3 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | |
|---|---|---|
| Turnover | 398,081,145 | 133,875,558 |
| Other Income Or Grants | 0 | 0 |
| Cost Of Sales | 204,967,830 | 64,086,746 |
| Gross Profit | 193,113,315 | 69,788,812 |
| Admin Expenses | 250,546,515 | 69,198,395 |
| Operating Profit | -57,433,200 | 590,417 |
| Interest Payable | 59,424,722 | 31,220,195 |
| Interest Receivable | 91,129,361 | 0 |
| Pre-Tax Profit | -25,728,560 | -30,629,778 |
| Tax | 14,444,781 | 817,501 |
| Profit After Tax | -11,283,779 | -29,812,278 |
| Dividends Paid | 0 | 0 |
| Retained Profit | -11,283,779 | -29,812,278 |
| Employee Costs | 568,466 | 22,708 |
| Number Of Employees | ||
| EBITDA* | -57,433,200 | 590,417 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | |
|---|---|---|
| Tangible Assets | 0 | 0 |
| Intangible Assets | 1,800,076,451 | 1,814,630,989 |
| Investments & Other | 1,659,981 | 1 |
| Debtors (Due After 1 year) | 6,901,824 | 104,706,683 |
| Total Fixed Assets | 1,808,638,256 | 1,919,337,673 |
| Stock & work in progress | 2,542,578 | 22,958,141 |
| Trade Debtors | 225,294,830 | 175,596,851 |
| Group Debtors | 4,900,461 | 31,145,257 |
| Misc Debtors | 0 | 0 |
| Cash | 2,345,016 | 124,896 |
| misc current assets | 4,291,121 | 0 |
| total current assets | 239,374,007 | 229,825,146 |
| total assets | 2,048,012,262 | 2,149,162,819 |
| Bank overdraft | 0 | 0 |
| Bank loan | 0 | 0 |
| Trade Creditors | 25,926,122 | 153,397,926 |
| Group/Directors Accounts | 163,748,391 | 89,007,645 |
| other short term finances | 0 | 0 |
| hp & lease commitments | 0 | 0 |
| other current liabilities | 117,116,796 | 11,824,994 |
| total current liabilities | 306,791,310 | 254,230,565 |
| loans | 705,705,851 | 894,543,183 |
| hp & lease commitments | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 |
| other liabilities | 0 | 110,390,583 |
| provisions | 1,933,237 | 2,393,459 |
| total long term liabilities | 707,639,089 | 1,007,327,227 |
| total liabilities | 1,014,430,399 | 1,261,557,793 |
| net assets | 1,033,581,864 | 887,605,026 |
| total shareholders funds | 1,033,581,864 | 887,605,026 |
| Mar 2024 | Mar 2023 | |
|---|---|---|
| Operating Activities | ||
| Operating Profit | -57,433,200 | 590,417 |
| Depreciation | 0 | 0 |
| Amortisation | 0 | 0 |
| Tax | 14,444,781 | 817,501 |
| Stock | -20,415,563 | 22,958,141 |
| Debtors | -74,351,676 | 311,448,791 |
| Creditors | -127,471,804 | 153,397,926 |
| Accruals and Deferred Income | 105,291,802 | 11,824,994 |
| Deferred Taxes & Provisions | -460,222 | 2,393,459 |
| Cash flow from operations | 29,138,596 | -165,382,635 |
| Investing Activities | ||
| capital expenditure | ||
| Change in Investments | 1,659,980 | 1 |
| cash flow from investments | ||
| Financing Activities | ||
| Bank loans | 0 | 0 |
| Group/Directors Accounts | 74,740,746 | 89,007,645 |
| Other Short Term Loans | 0 | 0 |
| Long term loans | -188,837,332 | 894,543,183 |
| Hire Purchase and Lease Commitments | 0 | 0 |
| other long term liabilities | -110,390,583 | 110,390,583 |
| share issue | ||
| interest | 31,704,639 | -31,220,195 |
| cash flow from financing | -35,521,914 | 1,980,138,520 |
| cash and cash equivalents | ||
| cash | 2,220,120 | 124,896 |
| overdraft | 0 | 0 |
| change in cash | 2,220,120 | 124,896 |
biosimilars newco limited Credit Report and Business Information
Biosimilars Newco Limited Competitor Analysis
Perform a competitor analysis for biosimilars newco limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mega companies, companies in WC2B area or any other competitors across 12 key performance metrics.
biosimilars newco limited Ownership
BIOSIMILARS NEWCO LIMITED group structure
Biosimilars Newco Limited has no subsidiary companies.
Ultimate parent company
MYLAN INC
#0059596
1 parent
BIOSIMILARS NEWCO LIMITED
14259834
biosimilars newco limited directors
Biosimilars Newco Limited currently has 5 directors. The longest serving directors include Ms Claire Mazumdar (Nov 2022) and Mr Peter Piot (Nov 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Claire Mazumdar | United Kingdom | 35 years | Nov 2022 | - | Director |
| Mr Peter Piot | United Kingdom | 76 years | Nov 2022 | - | Director |
| Mr John Walls | 80 years | Nov 2022 | - | Director | |
| Mr Nicholas Haggar | United Kingdom | 59 years | Nov 2023 | - | Director |
| Mr Rajendra Jatar | United Kingdom | 58 years | Jan 2024 | - | Director |
P&L
March 2024turnover
398.1m
+197%
operating profit
-57.4m
-9828%
gross margin
48.6%
-6.94%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
1b
+0.16%
total assets
2b
-0.05%
cash
2.3m
+17.78%
net assets
Total assets minus all liabilities
Similar Companies
biosimilars newco limited company details
company number
14259834
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
20140 - Manufacture of other organic basic chemicals
72110 - Research and experimental development on biotechnology
incorporation date
July 2022
age
3
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
DELOITTE IRELAND LLP
address
16 great queen street, covent garden, london, WC2B 5AH
Bank
HSBC BANK PLC, HSBC BANK PLC, HSBC BANK PLC
Legal Advisor
-
biosimilars newco limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to biosimilars newco limited. Currently there are 0 open charges and 1 have been satisfied in the past.
biosimilars newco limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BIOSIMILARS NEWCO LIMITED. This can take several minutes, an email will notify you when this has completed.
biosimilars newco limited Companies House Filings - See Documents
| date | description | view/download |
|---|
